ALIMTA(Pemetrexed)/Cisplatin and ALIMTA(Pemetrexed)/Carboplatin in Extensive Stage Small Cell Lung Cancer.

• Status: Completed
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to evaluate the effects (good and bad) of ALIMTA plus Carboplatin or ALIMTA plus Cisplatin on you and your small cell lung cancer.

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Eli Lilly and Company
• Treatments: Carboplatin; Cisplatin; Pemetrexed

Criteria

Inclusion Criteria:

• Have a diagnosis of extensive stage small cell lung cancer and can be treated with chemotherapy.

• Have received no prior chemotherapy for your disease.

• Have at least one measurable lesion.

• have an adequate performance status.

• Sign an informed consent form.

Exclusion Criteria:

• Have previously received chemotherapy for your lung cancer.

• Have been treated with a investigational drug within the last 30 days. Have previously completed or withdrawn from this study or any other study investigating ALIMTA.

• Have received radiation therapy within the last 1-2 weeks.

• Have brain metastasis that is uncontrolled.

• Have active infection or other serious condition.